Innoviva Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ The number of shares of registrant’s common stock outstanding on April 30, 2026 was 73,808,749. TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253Condensed Consolidated Statements of Income and Comprehensive Income for the Three Months Ended March 31, 2026and 20254Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026 and 20255Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20256Notes to Condensed Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations31Item 3. Quantitative and Qualitative Disclosures About Market Risk39Item 4. Controls and Procedures40PART II. OTHER INFORMATIONItem 1. Legal Proceedings40Item 1A. Risk Factors40Item 2. Unregistered Sales of Equity Securities and Use of Proceeds40Item 3. Defaults Upon Senior Securities41Item 4. Mine Safety Disclosure41Item 5. Other Information41Item 6. Exhibits42Signatures43 INNOVIVA, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except per share data) INNOVIVA, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(In thousands)(Unaudited) INNOVIVA, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited) INNOVIVA, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. Description of Operations and Summary of Significant Accounting Policies Description of Operations Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as “Innoviva”, the “Company”, or“we” and other similar pronouns) is a diversified biopharmaceutical company with a portfolio of royalties, a critical care andinfectious disease platform, and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partneredwith Glaxo Group Limited (“GSK”), including RELVAR®/BREO®ELLIPTA®(fluticasone furoate/vilanterol, “FF/VI”) andANORO®ELLIPTA®(umeclidinium bromide/ vilanterol, “UMEC/VI”). Under the Long-Acting Beta2 Agonist (“LABA”)Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO®ELLIPTA®as follows:15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties fromthe sales of ANORO®ELLIPTA®, which tier upward at a range from 6.5% to 10%. Our wholly owned, critical care and infectious disease operating platform, with a hospital focus, is anchored by a portfolioof four commercial and marketed products, as well as an FDA-approved product which is expected to be available to patients inthe second half of 2026: •GIAPREZA®(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;•XACDURO®(sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment ofhospital-acquired and ventilator-associated bacterial pneumonia caused byAcinetobacter;•XERAVA®(eravacycline) for the treatment of complicated intra-abdominal infections in adults;•ZEVTERA®(ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment ofstaphylococcus aureusbacteremia, in